GleamWall
中文EN

LPCN Lipocine Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1535955 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-13.4%
TTM net income YoY-70.4%
TTM EPS YoY-22.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-269.1%
Net margin-249.2%
FCF margin—
EBITDA margin-267.5%

Returns

ROE-52.9%
ROA-47.5%
ROIC (approx.)-55.3%
Asset turnover0.19x

Leverage & solvency

Liabilities / assets8.8%
Debt / equity0.00x
Current ratio11.36x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.07x
Accruals ratio3.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.98M$11.20M
R&D expense$8.58M$7.35M
SG&A expense$3.76M$5.00M
Operating income-$10.37M-$1.16M
Pretax income-$9.63M$9,033
Income tax$200$681
Net income-$9.63M$8,352
EBITDA-$10.31M-$1.11M
EPS (basic)-1.77—
EPS (diluted)-1.69—
Weighted avg. shares (diluted)5.71M5.42M
Balance sheet
Cash & equivalents$5.21M$6.21M
Short-term investments$9.72M$15.43M
Current assets$16.88M$22.32M
PP&E, net$104,293$165,075
Total assets$17.01M$22.51M
Current liabilities$2.53M$1.51M
Total liabilities$2.53M$1.51M
Shareholders' equity$14.48M$21.00M
Shares outstanding6.16M5.35M
Cash flow statement
Operating cash flow-$9.76M-$1.22M
Capital expenditure—$90,086
Free cash flow—-$1.31M
Investing cash flow$5.89M$2.45M
Financing cash flow$2.87M$209,340
Depreciation & amortization$60,782$41,106
Stock-based compensation$242,497$408,551

Free plan shows the latest 2 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.